Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 3;2(4):100161. doi: 10.1016/j.jacig.2023.100161

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 3 — The causal relationship between palivizumab exposure, RSV infection, and asthma development. Linear regression models showed that receiving palivizumab could decrease the incidence of RSV bronchiolitis hospitalization (coefficient, −0.10; P = .004) and RSV bronchiolitis hospitalization could increase future asthma development (coefficient, 0.31; P < .001). The direct influence of palivizumab on asthma development is nonsignificant (coefficient, −0.01; P = .884). Mediation analysis showed that palivizumab prophylaxis could decrease the onset of asthma through inhibition of RSV bronchiolitis hospitalization (coefficient, −0.02; P = .027).